Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study.

por Maria B Lyng, Anne-Vibeke Lænkholm, Qihua Tan, Werner Vach, Karina H Gravgaard, Ann Knoop, Henrik J Ditzel
Publicado 2013

The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine

por Elisabeth S Stovgaard, Karama Asleh, Nazia Riaz, Samuel Leung, Dongxia Gao, Lise B Nielsen, Anne-Vibeke Lænkholm, Eva Balslev, Maj-Britt Jensen, Dorte Nielsen, TO Nielsen
Publicado 2021

Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.

por Martin J Larsen, Torben A Kruse, Qihua Tan, Anne-Vibeke Lænkholm, Martin Bak, Anne E Lykkesfeldt, Kristina P Sørensen, Thomas V O Hansen, Bent Ejlertsen, Anne-Marie Gerdes, Mads Thomassen
Publicado 2013

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

por Sanne Løkkegaard, Daniel Elias, Carla L. Alves, Martin V. Bennetzen, Anne-Vibeke Lænkholm, Martin Bak, Morten F. Gjerstorff, Lene E. Johansen, Henriette Vever, Christina Bjerre, Tove Kirkegaard, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Linda S. Lindström, Laura J. Esserman, Anne E. Lykkesfeldt, Jens S. Andersen, Rikke Leth-Larsen, Henrik J. Ditzel
Publicado 2021